Dr. Peihong Wu, is a professor of Sun Yat-sen University, visiting professor of School of Medicine University of Rochester, USA, and visiting professor of School of Medicine University of Toronto, Canada. He is also the president of the Society of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association; and the director of the Department of Medical Image and Image Guided Therapy, Sun Yat-sen University Cancer Center.He has published 6 books, more than 130 papers in non-SCI journals and 40 peer-reviewed papers on image diagnosis and image-guided therapy in oncology. 

Background
1995-1998 Associate Professor and Vice Director, Department of Medical Image and Image Guided Therapy

1998-present Director and Professor of the Department of Medical Image and Image Guided Therapy, Sun Yat-sen University Cancer Center

1999-2000 Visiting scholar. Interventional Radiology and Imaging Diagnosis MD Anderson Cancer Center 

2001-present Member of Standing Committee of Interventional Therapy on Oncology, Chinese Anti-Cancer Association

2006-present President of the Society of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association2007-present Chairman of the Committee of Minimally Invasive Therapy and Integrated Therapy for Hepatocellular Carcinoma, Chinese Anti-Cancer Association

Honors
2007-present Member of Standing Committee of Chinese Anti-Cancer Association

2010-present Member of Academic Committee Sun Yat-sen University Cancer Center

2010-present Member of Medical Quality Management Committee Sun Yat-sen University Cancer Center

2013-present Award of TOP10DR in interventional radiology in China

2014-present Award of the most outstanding doctors in Sun Yat-sen University

2014-present Member of Board Director of Asian Tumor Ablation Association

2014-present Executive Member of Board Director of Asian Pacific Image-guided Therapy Association.

1. Combination of image-guided minimally invasive therapy with chemotherapy, radiotherapy and surgery.

2. Image-guided minimally invasive therapy combined with bio-immunotherapy.

3. Constructive model and strategy for cancer treatment: at the basis of effective elimination of malignant tumor, maximize the physical function, immunity and life quality of patients.

1982 M.D. Sun Yat-sen University, Guangzhou, China

1982-1985 Resident, Radiology and Clinical Oncology 

1985-1988 Fellow, Radiology and Interventional Radiology 

1988-1995 Attending Doctor, Department of Radiology and Interventional Radiology

Updated by International Office, Sun Yat-sen University Cancer Center

Prof. Huang Jinhua has engaged himself in professional clinical practice for over 20 years, accumulated abundant experience in interventional treatment and minimally invasive surgery for cancer and is proficient in curing cancers with various technologies of minimally invasive surgery and treatment. The primary interventional treatment technologies and the cancers cured include: 1. transarterial chemoembolization of liver cancer; 2. transarterial infusion of cancer; 3. ablation of liver cancer, lung cancer, kidney cancer and other solid tumors with radiofrequency and ablation; 4. comprehensive interventional and minimally invasive treatment for gynecologic refractory tumors; 5. implantation of radioactive particles into tumors; 6. (esophageal stricture, obstruction of biliary tract and venous stenosis) endovascular stent implantation.

1985: Graduated from School of Medicine, Medical College of Nanchang University (undergraduate)

1992: Obtained a master’s degree from Shanghai Jiao Tong University School of Medicine (SJTUSM)

2003 – 2004: Studied in MD Anderson Cancer Center, US

1. Radioablation settings affecting the size of lesions created ex vivo in porcine livers with monopolar perfusion electrodes. Acad Radiol 2010;17(8): 980-984.

2. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol 2010；16(45): 5766-5772.

3. CT, MRI, and FDG-PET/CT imaging findings of abdominopelvic desmoplastic small round cell tumors: Correlation with histopathologic findings. Eur J Radiol 2010.

4. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007，13(48):6593-6597.

Updated by International Office, Sun Yat-sen University Cancer Center

1987: Graduated from undergraduate medical program at Inner Mongolia Medical University.

1997: Obtained a master’s degree in medical imaging and nuclear medicine from Norman Bethune College of Medicine Jilin University.

2006: Obtained a doctoral degree in medical imaging and nuclear medicine from Second Military Medical University

09/2008-12/2008: Acted as a visiting scholar in the Department of Radiology, U.S. Baylor College of Medicine

1．Osteosarcoma:Limb salvaging treatment by ultrasonogrphically guided high intensity focused ultrasound.CancerBiolTher 2009;(12)1102-1108

2．Superficial malignant tumors:Non-invasive treatment with ultrasonographically guided high-Intensity focused ultrasound.CancerBiolTher 2009;8(24)(December15;2009)

3．Short to mid term evaluation of CT-guided I125 brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma.CancerBiol Ther.2009;8(7):585-590

4. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 2010 Nov;136(11):1633-40

5. Noninvasive treatment of malignant bone tumors using high-intensity focused ultrasound.Cancer. 2010 Aug 15;116(16):3934-42.

6. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. European Journal Cancer. 2010 Sep;46(13):2513-21

7. Microwave ablation treatment of liver cancer with 2,450-MHz cooled-shaft antenna: an experimental and clinical study.Journal of Cancer Research and Clinical Oncology. 2010 Oct;136(10):1507-16

8. An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity.Contrast Media Mol Imaging. 2010 Nov 30. [Epub ahead of print]

9. Computed tomography and magnetic resonance imaging findings of peripheral primitive neuroectodermal tumors of the head and neck. European Journal of Radiology. 2011 Feb [Epub ahead of print]

10. Ke, S. and F. Zhang, et al. (2012). "Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model." CurrMol Med 12 (8): 944-51.

11.Hu, X. and H. Qiu, et al. (2012). "Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy." Cancer BiolTher 13 (10): 840-7.

12. Peng, S. and Q. X. Yang, et al. (2014). "Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma." Asian Pac J Cancer Prev 15 (13): 5155-60.

13. Yang, G. and S. Zhang, et al. (2014). "Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1." Biochim Biophys Acta 1839 (9): 837-48.

14. Yang, G. and S. Zhang, et al. (2014). "The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin." J Exp Clin Cancer Res 33: 53.

15. Zhang, T. and M. Lu, et al. (2014). "CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy." J Cancer Res Clin Oncol 140 (8): 1383-90.

16. Yang, G. and S. Peng, et al. (2014). "Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin." Recent Pat Anticancer Drug Discov 9 (2): 258-63.

17. Zhang, W. and Y. Zhang, et al. (2014). "Multi-modality imaging to determine the cellular heterogeneity of nasopharyngeal  carcinoma components." Oncotarget 5 (8): 2221-9.

18. Liu, Z. and F. Gao, et al. (2014). "Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis." Tumour Biol.

Updated by International Office, Sun Yat-sen University Cancer Center

Professor Weijun Fan is currently deputy director of Department of Minimally Invasive Interventional Therapy at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China.  As the leader of the First Tumor Ablation Training Course of the Chinese Medical Doctor Association (CMDA), professor Fan has pioneered the Chinese Medical Doctor Association's tumor ablation training. So far, the Training Course has trained more than 5,000 ablation professionals for all provinces and municipalities across the country. As the leader of the tumor ablation training expert group, he participated in the organization of 29 sessions of ablation training, and organized the compilation of the first set of tumor ablation training materials of the CMDA, which has made great contributions to the cause of tumor ablation in China. Professor Fan Weijun edited the first monograph on microwave ablation of tumors called “Microwave Ablation Therapy for Tumors”, which laid the foundation for the popularization of tumor microwave ablation technology in China. Moreover, he organized the "Expert Consensus for Thermal Ablation for Primary and Metastatic Lung Tumors" and "Expert Consensus for Image-guided Adrenal Tumor Ablation Treatment".  

Professor Fan is currently the chairman of the ablation committee of the CMDA intervention branch; the leader of the tumor ablation treatment technology expert group of the CMDA; the candidate of the chairman of the professional committee member of the tumor ablation treatment of the CHINESE ANTI CANCER ASSOCIATION (CACA); Deputy Director of the Tumor Ablation Therapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Chairman of the Respiratory Intervention Special Committee of the Interventional Group of the Chinese Society of Radiology (CSR); the candidate of the chairman of the Professional Committee of Tumor Minimally Invasive Therapy of Guangdong Anticancer Association. Besides, Professor Fan is the Chinese deputy Editor-in-Chief of “Journal of Cancer Research and Therapeutics”. And he also is the editorial board member of "Interventional Radiology" and "Anatomy and Clinical Medicine". At present, he has published fifties of papers.

More than fifty papers were published in core Journals in China, and more than twenty SCI papers were published on multiple magazines, such as Cancer, Aging, Cancer Immunology Immunotherapy, International Journal of Hyperthermia, AJR, and JVIR.

1.Xin Li,Weijun Fan, Liang Zhang, Ming Zhao, Zilin Huang, Wang Li, Yangkui Gu, Fei Gao, Jinhua Huang, Chuanxing Li, Fujun Zhang, Peihong Wu, CT-Guided Percutaneous Microwave Ablation of Adrenal Malignant Carcinoma, Cancer,2011.11.15，117(22):5182~5188

2.Cao F, Shen L, Qi H, Xie L, Song Z, Chen S,Fan W: Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging (Albany NY) 2019, 11(21):9544-9555. 

3.Shen L, Qi H, Chen S, Cao F, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, Wen X, Chen Q, Li W, Zhang X,Fan W. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol Immunother. 2020. doi: 10.1007/s00262-020-02566-z.

4. Fan WeiJun, Li Xin, Zhang Liang, Jiang Hua, Zhang JianLei, Comparison of Microwave Ablation and Multipolar Radiofrequency Ablation In Vivo Using Two Internally Cooled Probes, American Journal of Roentgenology, 2012.1.01，198(1):W46~W50

5.Li Xin, Zhang Liang,Fan Weijun, Zhao Ming, Wang Ligang, Tang Tian, Jiang Hua, Zhang Jianlei, Liu Yanfeng, Comparison of microwave ablation and multipolar radiofrequency ablation, both using a pair of internally cooled interstitial applicators: Results in ex vivo porcine livers, INTERNATIONAL JOURNAL OF HYPERTHERMIA，2011.01.01, 27(3):240~248

6.Xie L, Cao F, Qi H, Song Z, Shen L, Chen S, Hu Y, Chen C,Fan W: Efficacy and safety of CT-guided percutaneous thermal ablation for hepatocellular carcinoma adjacent to the second porta hepatis. Int J Hyperthermia 2019, 36(1):1122-1128.

7.Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, Xie L, Wu Y, Chen G, Mo J, Zhu G, Ye D, Zhang Y, Feng Z, Xu L,Fan W: Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J Hyperthermia 2020, 37(1):384-391.

8.Li Xin,Fan Weijun, Zhang Liang, Zhang Xiao-ping, Jiang Hua. Zhang  Jian-lei, Zhang Hao, CT-guided Percutaneous Microwave Ablation of Liver Metastases from Nasopharyngeal Carcinoma, JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2013.5.01, 24(5):680~684

9.Qiuxia Yang, Han Qi, Rong Zhang, Chao Wan, Ze Song, Liang Zhang, Weijun Fan. Risk Factors for Local Progression after Percutaneous Radiofrequency Ablation of Lung Tumors: Evaluation Based on a Review of 147 Tumors, J Vasc Interv Radiol，2017.01.19

10.Qi H,Fan W. Value of ablation therapy in the treatment of lung metastases. Thoracic Cancer. 2017 doi:10.1111/1759-7714.12567

11.Cao F, Xie L, Qi H, Chen S, Shen L, Song Z,Fan W: Safety and efficacy of thermal ablation for subpleural lung cancers. THORAC CANCER 2019, 10(6):1340-1347.

12.Cao F, Wan C, Xie L, Qi H, Shen L, Chen S, Song Z,Fan W: Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation. THORAC CANCER 2019, 10(6):1369-1377.

13.Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L,Fan W: Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma A Propensity Score Matching Analysis. CANCER MANAG RES 2019, 11:9321-9330.

Updated April 2021 by International Office, Sun Yat-sen University Cancer Center

Zhao Ming was appointed as the associate chief physician, associate professor and advisor of master’s degree student at Sun Yat-sen University Cancer Center. He is familiar with human imaging anatomy and imaging vascular anatomy and proficient in interventional diagnosis and treatment for solid tumors, such as interventional chemoembolization and radiofrequency ablation of primary liver cancer and metastatic colorectal cancer, integrated application of molecular targeted therapy, radiofrequency ablation of lung cancer and lung metastatic tumors and integrated application of TACE, TAI and molecular targeted therapy; palliative treatment for advanced tumors, such as drainage of and stent implantation of obstructive jaundice, stent implantation in the esophagus, stent implantation in the vena cava, image-guided implantation of radioactive particles under, nerve compression and interventional treatment for pain palliation of metastatic bone tumors. He is able to grasp the developments in cancer treatment and provide out-patient medical advice and popularization of science, and attends clinical and multidisciplinary consultations on hepatobiliary diseases for chief scientists. With regard to single diseases, he owns an in-depth research on and abundant clinical experience in hepatic metastases, which he also regards as his basis for research.

Guided by the concept of single disease sand multidisciplinary integrated treatment, he systematically carries out clinical research on liver tumors and solid tumors in the lung and gradually implements the concept of integrating interventional treatment and minimally invasive surgery planning system into individualized treatment; conducts real-time ablation treatment for tumors under the guidance of MRI and performs local treatment for such solid cancers as liver cancer, lung cancer and retroperitoneal cancer with various means of minimally invasive surgery including nano-knife. Taking prolong survival as the goal, he analyzes factors concerning the systemic immunity of tumors’ recurrence and gradually takes measures of intervention clinical treatment by studying immune regulation of recurrent primary liver cancer and its immune tolerance mechanism.

January 2014: appointed as the Chief Physician of Sun Yat-sen University Cancer Center;
April 2011-September 2013: studied at Brigham and Women’s Hospital, Harvard University and worked on medical research on basis for immunology and transformation of tumors;

September 2008: short-term study in Barcelona Clinic Liver Cancer (BCLC);
2002-2006: Studied interventional treatment and minimally invasive surgery for liver cancer and obtained the doctoral degree in oncology;

1997-2000: received specialist training of cancer and obtained a master’s degree in oncology from Sun Yat-sen University (former Sun Yat-sen University of Medical Sciences);

1993-1997: completed clinical training for resident physicians at the First Affiliated Hospital of Bengbu Medical College

1. Percutaneous CT-guided radiofrequency ablation as supplemental therapy after systemic chemotherapy for selected advanced non-small cell lung cancers. Am J Roentgenol.2013;201(6):1362-7.

2. Transcriptomic profiling of Aspergillusflavus in response to 5-azacytidine. Fungal Genet Biol. 2013;56:78-86.

3. Chromosomal evolution of Escherichia coli for the efficient production of lycopene. BMC Biotechnol 2013;13(1):6.

4. Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. International Journal of Hyperthermia 2012;28:721-728.

5. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012;81(10):2717-2725.

6. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation. Eur J Radiol 2012;81(4):e473-e477.

7. Retroperitoneal schwannoma treated with percutaneous computed tomography-guided radiofrequency ablation. J Neurosurg Spine 2012;17(2):173-176.

8. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature. Exp Ther Med 2012; 4:334-338

9. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma. Int J Hyperthermia 2011; 27(6):549-554.

10. Huge refractory retroperitoneal nerve sheath tumor treated with radiofrequency ablation: a case report with literature review. Chin J Cancer 2010; 29(4):463-6.

Updated by International Office, Sun Yat-sen University Cancer Center

Prof. Gao obtained his Ph.D. at Sun Yat-sen University Cancer Center, P. R. China in 2012. He subsequently completed his postdoctoral research fellowship program at University of Rochester University Medical Center (URMC, USA). He has rich clinical experience in minimally invasive and interventional treatment of hepatocellular carcinoma with portal hypertension (especially TIPS procedure), radiofrequency (microwave) ablation, radioactive seed implantation of solid tumor and biliary stent implantation for malignant obstructive jaundice. As the sponsor and executive chairman, he had hosted 8 consecutive "China Southern TIPS Forum". As the first author and/or corresponding author, Prof. Gao has published over 60 papers in prestigious, international peer-reviewed journals, such as Radiology and European Radiology. He has been supported by the National Natural Science Foundation of China (NSFC) and National Natural Science Foundation of Guangdong, etc.

Prof. Gao has received the First prize of scientific and technological progress of Guangdong Province (2020); Second prize of scientific and technological progress award of China Anti-Cancer Association (2019); "The cutting edge of intervention in China" (2019, CCI); "National Famous doctors in China: Young Pioneer" (2017); Research Fellowship of URMC (University of Rochester Medical Center, USA); "The second prize of national outstanding young interventional physician research award (2015)"; "The first prize of the excellent paper in the 16th Annual Conference of Chinese Interventional Brachyseed Society (CIBS)"; etc.

1.Microwave ablation for solid tumors.

2.Study on the advantage of treatment for hepatic carcinoma with hypersplenism by TACE combined with splenic microwave ablation.

3.Biliary stents placement

6/20/2003 Bachelor of Medical ImagingSun Yat-sen UniversityGuangzhou, China

6/22/2009 Master of Medical ImagingSun Yat-sen University Guangzhou, China

6/26/2012 M.D. of Oncology,Sun Yat-sen University Guangzhou, China

1.Wenliang Zhu#, Zhenkang Qiu#, Huzheng Yan, Zhihui Zhong, Weiwei Jiang, Fujun Zhang,* and Fei Gao* .Retrograde venous coil embolization prior to transarterial chemoembolization in hepatocellular carcinoma with arterio-hepatic venous shunts. Diagn Interv Radiol. 2022 28(6): 616–620.
2.Huzheng Yan#, Zhenkang Qiu#, Zhanwang Xiang, Kai Feng, Mingsheng Huang*, Fei Gao*. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience. Cancer Imaging. 2022; 22: 13.  
3.Zhenkang Qiu#, Wenliang Zhu#, Huzheng Yan, Guobao Wang, Mengxuan Zuo, Han Qi, Guisong Wang, Weiwei Jiang, Jingbing Xue, Fujun Zhang*, Fei Gao*. Single-Centre Retrospective Study Using Propensity Score Matching Comparing Left Versus Right Internal Jugular Vein Access for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation. Cardiovasc Intervent Radiol. 2022; 45(5): 563–569.
4.Zhenkang Qiu#, Guobao Wang#, Guang Yang, Guisong Wang, Weiwei Jiang, Zixiong Chen, Wenliang Zhu, Huanqing Guo, Fujun Zhang*, Fei Gao*. Transcriptome sequencing-based personalized analysis of hepatocellular carcinoma patients with portal vein tumor thrombus. J Gastrointest Oncol. 2021 Apr; 12(2): 795–805. 
5.Zixiong Chen#, Xiaobo Fu#, Zhenkang Qiu, Maoyuan Mu, Weiwei Jiang, Guisong Wang, Zhihui Zhong, Han Qi*, Fei Gao*. CT-guided 125I Brachytherapy for Hepatocellular Carcinoma in High-risk Locations after Transarterial Chemoembolization Combined with Microwave Ablation: A Propensity Score-matched Study Radiol Oncol. 2023 Mar; 57(1): 127–139. 
6.Zhenkang Qiu#, Guobao Wang#, Huzheng Yan, Han Qi, Mengxuan Zuo, Guisong Wang, Weiwei Jiang, Zixiong Chen, Jingbing Xue, Ligong Lu, Fujun Zhang*, Fei Gao*. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. Eur Radiol. 2022; 32(10): 6777–6787. 
7.Huzheng Yan#, Guobao Wang#, Wenliang Zhu, Kai Feng, Wenke Zhu, Xuan Wu, Zhenkang Qiu, Guanyu Chen, Weiwei Jiang, Fujun Zhang*, Fei Gao*. Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Transl Oncol. 2020 Dec; 13(12): 100864. 
8.Huzheng Yan#, Ma Luo#, Lifei Wang, Zhenkang Qiu, Zhiqiang Mo, Zhanwang Xiang, Yanling Zhang, Guanyu Chen, Zhihui Zhong, Xiuchen Wang, Fei Gao*, Fujun Zhang*. Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes. Cancer Imaging. 2020; 20:25. 
9.Zhenkang Qiu, Gui Song Wang, Fei Gao. Whole-course management of interventional treatment in liver cancer patients with portal hypertension J Interv Med. 2019 May; 2(2): 52–54.Correction in: J Interv Med. 2020 Dec; 3(4): 216.
10.Xiaobo Fu#, Weiwei Jiang#, Maoyuan Mu, Guobao Wang, Han Qi, Zixiong Chen, Mengxuan Zuo*, Fei Gao*. Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by three‐dimensional reconstruction volumetry. Cancer Med. 2023 Apr; 12(8): 9506–9516.
11.Ye Sheng#, Xiaobo Fu#, Guobao Wang, Maoyuan Mu, Weiwei Jiang, Zixiong Chen, Han Qi*, Fei Gao*. Safety and efficacy of self-expandable metallic stent combined with 125I brachytherapy for the treatment of malignant obstructive jaundice. Cancer Imaging. 2023; 23: 33. 
12.Wang G, Zhang F, Yang B, Xue J, Peng S, Zhong Z, Zhang T, Lu M, Gao F*.   Feasibility and Clinical Value of CT-guided (125)I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma. Radiology. 2016 Mar;278(3):897-905. 
13.Mo Z#, Zhang T#, Zhang Y, Xiang Z, Yan H, Zhong Z, Gao F*, Zhang  F*.   Feasibility  and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure. Eur Radiol. 2018 Mar;28(3):1194-1203. 
14. Yan H#, Xiang Z#, Zhong Z#, Mo Z, Zhang T, Chen G, Zhang F*, Gao F*. CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region. Transl Oncol. 2017 Feb;10(1):90-98. 
15. Yan H#, Mo Z#, Xiang Z, Rong D, Zhang Y, Chen G, Zhong Z, Zhang F*, Gao F*. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer. 2017 Jul 5;8(11):2104-2113. 
16. Xiang Z#, Mo Z#, Li G#, Gilani S, Zhong Z, Zhang T, Zhang F*, Gao F*. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Oncotarget. 2016 Apr 5;7(14):18384-93. 
17. Gao F, Li C, Gu Y, Huang J, Wu P. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients. Eur J Radiol 2013; 82(2):e70-75. 
18.  Zhang T#, Lu M#, Peng S, Zhang W, Yang G, Liu Z, Singh S, Yang Y, Zhang F*, Gao F*. CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol 2014;140(8):1383-1390. 
19.  Yang G#, Peng S#, Zhang Y, Liu Z, Lu M, Zhang T, Gao F*, Zhang F*. Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin. Recent Pat Anticancer Drug Discov 2014; 9(2):258-263.
20.  Yang G#, Zhang S#, Gao F#, Liu Z, Lu M, Peng S, Zhang T, Zhang F. 
Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1. Biochim Biophys Acta. 2014; 1839(9):837-848.   
21.  Gao F, Gu YK, Huang JH, Zhao M, Wu PH*. Radiofrequency Ablation of Retroperitoneal Metastatic Lymph Nodes from Hepatocellular Carcinoma, Acad Radiol; 2012; 19(8):1035-1040. 
22.  Gao F, Gu YK, Fan WJ, Zhang L, Huang JH*, Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma. World J Gastroenterol; 2011; 17(26):3145-3150.   
23.  Gao F, Gu YK, Shen JX, Li CL, Jiang XY, Huang JH*, Experimental study of  destruction to porcine spleen in vivo by microwave ablation. World J Gastroenterol; 2011; 17(45):5014-5020. 
24. Gao F#, Zhong R#, Li GH, Zhang WD*. Computed tomography and magnetic  resonance imaging findings of inflammatory myofibroblastic tumors of the head  and neck. Acta Radiol, 2014; 55(4):434-440.   
25.  Gao F, He N, Wu PH*. The number of tumor-free axillary lymph nodes removed as a prognostic parameter for node-negative breast cancer. Chin J   2014, 33(11):569-73.
26.  Gao F#, Wang GB#, Xiang ZW#, Yang B, Xue JB, Mo ZQ, Zhong ZH, Zhang T, Zhang FJ *, Fan WJ *. A preoperative mathematic model for computed tomographic guided microwave ablation treatment of hepatic dome tumors. Oncotarget. 2016 May 3;7(18):25949-25959. 
27.  Liu Z#, Gao F#, Yang G, Singh S, Lu M, Zhang T, Zhong  Z, Zhang F, Tang R. Combination of radiofrequency ablation with transarterial  chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol, 2014; 35(8):7407-7413.  
28.  Jingxian Shen, Fei Gao*, Jing Zhao, Yunxian Mo, Peihong Wu. Small hepatocellular carcinoma keeping hypodense during dual phase helical CT scan and correlative pathology, J Biomed Graph Comput, 2013; 3(4):1-7. 
29.  Yongxin Chen, Fei Gao*, Lin Chen, Sheng Peng, Yingjie Huang, Yao Wang. Effectiveness and Safety of CT-Guided 125I Brachytherapy for Lung Metastasis from Hepatocellular Carcinoma. Open Journal of Radiology, 2013; 3:159-164. 
30. Zhanwang Xiang#, Lifei Wang#, Huzheng Yan, Zhihui Zhong, Wangkai Liu, Zhiqiang Mo, Fei Gao*, Fujun Zhang*. 125I seed brachytherapy versus external beam radiation therapy for the palliation of painful bone metastases of lung cancer after one cycle of chemotherapy progression. Oncotarget and Therapy, 2018,11:5183-5193.

Updated by International Office, Sun Yat-sen University Cancer Center

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Gu Yangkui graduated from Sun Yat-sen University of Medical Sciences in 1998 and has worked in the University after obtaining a master’s degree from Sun Yat-sen University in 2002. She completed the training for resident doctors and chief physician at Sun Yat-sen University Cancer Center and was promoted as Associate chief physician in December 2010.

Dr. Gu Yangkui possesses rich clinical experience in minimally invasive surgery of primary liver cancer and colorectal liver metastases and specializes in ablation of liver cancer and stent implantation of various stenosis.

Updated by International Office, Sun Yat-sen University Cancer Center

1. Dynamic prognostication and treatment of cancer using big data. 

2. Enhancing efficacy of immunotherapy through local modulation.

Sun Yat-sen University (SYSU), Major GPA: 3.6/5.0      

Sept. 2007-July, 2015 Clinical Medicine (8-year-program)

1.Shen L#,Chen Q#, Yang C#, Wu Y#, Yuan H, Chen S, Ou S, Jiang Y, Huang T, Ke L,Mo J,Feng Z, Zhou P, Fan W. Role of PRDM1 in Tumor Immunity and Drug Response: APan-Cancer Analysis. FrontPharmacol. 2020 Dec 15;11:593195.

2.Shen L#,Qi H#, Chen S#, Cao F#, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, WenX, Chen Q, Li W, Zhang X, Fan W. Cryoablation combined with transarterialinfusion of pembrolizumab (CATAP) for liver metastases of melanoma: anambispective, proof-of-concept cohort study. CancerImmunol Immunother. 2020 Sep;69(9):1713-1724.

3. Shen L,Chen S, Qiu Z, Qi H, Yuan H, Cao F, Xie L, Chen Q, Li W, Fan W. Transarterialchemoembolization combined with apatinib versus transarterial chemoembolizationalone for hepatocellular carcinoma with macroscopic vascular invasion: Apropensity score matching analysis. JCancer Res Ther. 2020 Sep;16(5):1063-1068. doi:10.4103/jcrt.JCRT_801_19.

4.Shen L#,Zeng Q#, Guo P#, Huang J#, Li C, Pan T, Chang B, Wu N, Yang L, Chen Q, Huang T,Li W*, Wu P*. Dynamically prognosticating patients with hepatocellularcarcinoma through survival paths mapping based on time-series data. Nat Commun. 2018 Jun 8;9(1):2230

5.Shen L#,Xi M#, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, HuangJ. Combination Therapy after TACE for Hepatocellular Carcinoma with MacroscopicVascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel). 2018 Dec14;10(12).

6.Shen LJ#,Wang L#, Wang SY, Xie GF, Zeng Q, Shi F, Zhang Y, Wu M, Shu WH, Pan CC, Xia YF,Wu PH*. Imaging-based multi-level subdivision of M1 category in TNM stagingsystem for metastatic nasopharyngeal carcinoma. Radiology.2016 Sep; 280(3):805-14

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center